Summary of SKYE's Q3 2025 Earnings Call

1Key Financial Results and Metrics

Cash Position: SKYE ended Q3 2025 with cash and cash equivalents totaling $35.3 million, expected to fund operations and key clinical milestones into 2027.

R&D Expenses: Increased to $9.4 million from $4.9 million in Q3 2024, driven by contract manufacturing and clinical trial costs.

General and Administrative Expenses: Decreased to $3.9 million from $4.6 million in Q3 2024.

Net Loss: Reported at $12.8 million, compared to $3.9 million in Q3 2024, with non-cash share-based compensation remaining stable at $1.9 million.

2Strategic Updates and Business Highlights

Nimazumab Development: Positive data from the Phase 2a CBEYOND study indicated synergistic efficacy when combined with semaglutide, achieving an additional 3% weight loss at 26 weeks.

Clinical Insights: The study demonstrated improved lean-to-fat mass ratios and reduced waist circumference, with no neuropsychiatric signals or significant GI burden observed.

Extension Study: Enrollment for a 26-week extension study was completed with 43 patients, and retention rates were strong.

Manufacturing and CMC: Progress made in high concentration formulation strategy to enhance scalability and reduce costs, aligning with market demands.

3Forward Guidance and Outlook

SKYE is focused on refining the dose of Nimazumab to unlock its therapeutic potential and plans to present updated data at major scientific conferences in 2026.

The company aims to finalize the next Phase 2 design, concentrating on both combination and maintenance indications, with results from the extension study expected in late Q1 2026.

4Bad News, Challenges, or Points of Concern

Increased Net Loss: The significant rise in net loss raises concerns about financial sustainability, particularly with rising R&D costs.

Small Sample Size: Questions were raised regarding the statistical significance of data from the 26-week extension study due to the low enrollment of 43 patients.

Regulatory Path: Uncertainty remains about the need for monotherapy approval before pursuing maintenance therapy, which could complicate the development timeline.

Safety Concerns: While current data shows no neuropsychiatric adverse events, the potential for GI issues at higher doses remains a concern.

5Notable Q&A Insights

Analysts inquired about the relationship between drug exposure and weight loss, with responses indicating a positive correlation and a need for higher dosing to achieve better efficacy.

Concerns about the rapid weight regain observed in the semaglutide arm were discussed, with the company acknowledging the need to understand patient baseline characteristics.

Feedback from key opinion leaders (KOLs) was generally positive, particularly regarding the potential for Nimazumab to offer a differentiated mechanism for weight maintenance.

The management emphasized their commitment to maintaining a disciplined approach to clinical development and timely execution of milestones. Overall, SKYE Bioscience, Inc. is making significant strides in its clinical development of Nimazumab, although it faces challenges related to financial losses and regulatory complexities. The upcoming data releases and strategic focus on dose optimization and combination therapies will be crucial for the company's future trajectory.